Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Date: September 1, 2011
Pages: 77
Price:
US$ 3,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M56058C3A14EN
Leaflet:

Download PDF Leaflet

Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Macular Degeneration Therapeutics market. The report identifies the key trends shaping and driving the global Macular Degeneration Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Macular Degeneration Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Macular Degeneration Therapeutics market. Its Scope includes -
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Macular Degeneration Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Macular Degeneration Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Macular Degeneration Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Macular Degeneration Therapeutics market
Reasons to buy

The report will enhance your decision making capability. It will allow you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Macular Degeneration Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Macular Degeneration Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global Macular Degeneration Therapeutics market landscape? - Identify, understand and capitalize.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 MACULAR DEGENERATION THERAPEUTICS - INTRODUCTION

2.1 Disease Overview
  2.1.1 Classification of AMD
  2.1.2 Dry AMD
  2.1.3 Wet AMD
2.2 Etiology and Pathophysiology
2.3 Epidemiology
  2.3.1 Global
  2.3.2 The US
  2.3.3 The UK
  2.3.4 Germany
  2.3.5 Spain
  2.3.6 Italy
  2.3.7 France
  2.3.8 Japan
  2.3.9 Pharmaco-economic Burden
  2.3.10 Quality of Life (QoL)
2.4 Signs and Symptoms
2.5 Diagnosis
  2.5.1 History
  2.5.2 Examination
2.6 Treatment and Management Pattern
  2.6.1 Assessment and Treatment Plans for AMD
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance

3 MACULAR DEGENERATIONTHERAPEUTICS - MARKET CHARACTERIZATION

3.1 Overview
3.2 Macular Degeneration Therapeutics Market Size
3.3 Macular Degeneration Therapeutics Market Size (2005-2010) - Global
3.4 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Global
3.5 Macular Degeneration Therapeutics Market Size (2005-2010) - The US
3.6 Macular Degeneration Therapeutics Market Forecast (2010-2018) - The US
3.7 Macular Degeneration Therapeutics Market Size (2005-2010) - France
3.8 Macular Degeneration Therapeutics Market Forecast (2010-2018) - France
3.9 Macular Degeneration Therapeutics Market Size (2005-2010) - Germany
3.10 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Germany
3.11 Macular Degeneration Therapeutics Market Size (2005-2010) - Italy
3.12 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Italy
3.13 Macular Degeneration Therapeutics Market Size (2005-2010) - Spain
3.14 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Spain
3.15 Macular Degeneration Therapeutics Market Size (2005-2010) - The UK
3.16 Macular Degeneration Therapeutics Market Forecast (2010-2018) - The UK
3.17 Macular Degeneration Therapeutics Market Size (2005-2010) - Japan
3.18 Macular Degeneration Therapeutics Market Forecast (2010-2018) - Japan
3.19 Drivers and Barriers for the Macular Degeneration Therapeutics Market
  3.19.1 Drivers for the Macular Degeneration Therapeutics Market
  3.19.2 Barriers for the Macular Degeneration Therapeutics Market
3.20 Opportunity and Unmet Need Analysis
3.21 Key Takeaway

4 MACULAR DEGENERATION THERAPEUTICS - COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the AMD Therapeutics market
  4.3.1 Lucentis (ranibizumab)
  4.3.2 Visudyne (verteporfin)
  4.3.3 Macugen (pegatanib sodium)
  4.3.4 Avastin (bevacizumab)
4.4 Key Takeaway

5 MACULAR DEGENERATION THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Macular Degeneration Therapeutics Pipeline - Pipeline by Phases of Development
  5.3.1 Macular Degeneration Therapeutics - Phase III Pipeline
  5.3.2 Macular Degeneration Therapeutics - Phase II Pipeline
  5.3.3 Macular Degeneration Therapeutics - Phase I Pipeline
  5.3.4 Macular Degeneration Therapeutics - Pre-clinical Pipeline
  5.3.5 Macular Degeneration Therapeutics - Discovery Pipeline
5.4 Technology Trends Analytic Framework
5.5 Macular Degeneration Therapeutics Market - Pipeline by Mechanism of Action
5.6 Macular Degeneration Therapeutics - Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
  5.7.1 Eylea (VEGF Trap-Eye)
5.8 Key Takeaway

6 MACULAR DEGENERATION THERAPEUTICS - CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Macular Degeneration Therapeutics Clinical Trials

7 STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
7.3 Macular Degeneration Therapeutics - Implications for Future Market Competition

8 MACULAR DEGENERATION THERAPEUTICS - FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles
  8.2.1 Genentech /F. Hoffmann-La Roche
  8.2.2 Bayer AG
  8.2.3 Regeneron Pharmaceuticals, Inc.
8.3 Other Companies in AMD Therapeutics Market

9 MACULAR DEGENERATION THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS10 MACULAR DEGENERATION THERAPEUTICS - APPENDIX

10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
  10.3.1 Coverage
  10.3.2 Secondary Research
  10.3.3 Forecasting
  10.3.4 Primary Research
  10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

LIST OF TABLES

Table 1: Treatment Recommendations and Follow-Up for Non-neovascular AMD
Table 2: Treatment Recommendations and Follow-Up for Neovascular AMD
Table 3: Macular Degeneration Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 4: Macular Degeneration Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 5: Macular Degeneration Therapeutics Market, the US, Revenue ($m), 2005-2010
Table 6: Macular Degeneration Therapeutics Market, the US, Forecast ($m), 2010-2018
Table 7: Macular Degeneration Therapeutics Market, France, Revenue ($m), 2005-2010
Table 8: Macular Degeneration Therapeutics Market, France, Forecast ($m), 2010-2018
Table 9: Macular Degeneration Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 10: Macular Degeneration Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 11: Macular Degeneration Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 12: Macular Degeneration Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 13: Macular Degeneration Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 14: Macular Degeneration Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 15: Macular Degeneration Therapeutics Market, the UK, Revenue ($m), 2005-2010
Table 16: Macular Degeneration Therapeutics Market, the UK, Forecast ($m), 2010-2018
Table 17: Macular Degeneration Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 18: Macular Degeneration Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 19: Macular Degeneration Therapeutics - Phase III Pipeline, 2011
Table 20: Macular Degeneration Therapeutics - Phase II Pipeline, 2011
Table 21: Macular Degeneration Therapeutics - Phase I Pipeline, 2011
Table 22: Macular Degeneration Therapeutics - IND Filing Pipeline, 2011
Table 23: Macular Degeneration Therapeutics- Pre-clinical Pipeline, 2011
Table 24: Macular Degeneration Therapeutics - Discovery Pipeline, 2011
Table 25: AMD Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 26: Macular Degeneration Therapeutics - Clinical Trials by Country, 2011
Table 27: Macular Degeneration Therapeutics - Clinical Trials by Phase, 2011
Table 28: Macular Degeneration Therapeutics - Clinical Trials by Status, 2011
Table 29: Macular Degeneration Therapeutics - Prominent Sponsors, 2011
Table 30: Macular Degeneration Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 31: F. Hoffman-La Roche - Ophthalmology Pipeline, 2011
Table 32: F. Hoffman-La Roche - Deals 2009-2010
Table 33: Bayer AG - AMD Pipeline, 2011
Table 34: Bayer AG Deals, 2009-2010
Table 35: Regeneron - AMD Pipeline, 2011
Table 36: Macular Degeneration Therapeutics Market - Future Players, 2011
Table 37: Macular Degeneration Therapeutics, Global, Deals, 2009-2011

LIST OF FIGURES

Figure 1: Stages of Dry Age-Related Macular Degeneration
Figure 2: Classification of Age-Related Macular Degeneration
Figure 3: Stages of Age-related Macular Degeneration
Figure 4: Established And Possible Risk Factors-Age Related Macular Degeneration
Figure 5: The Amsler Grid Test
Figure 6: Optometric Management of the Patient with Age-related Macular Degeneration
Figure 7: Referral Pathway Age Related Macular Degeneration
Figure 8: Macular Degeneration Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 9: Macular Degeneration Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 10: Macular Degeneration Therapeutics Market, the US, Revenue ($m), 2005-2010
Figure 11: Macular Degeneration Therapeutics Market, the US, Forecast ($m), 2010-2018
Figure 12: Macular Degeneration Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 13: Macular Degeneration Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 14: Macular Degeneration Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 15: Macular Degeneration Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 16: Macular Degeneration Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 17: Macular Degeneration Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 18: Macular Degeneration Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 19: Macular Degeneration Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 20: Macular Degeneration Therapeutics Market, the UK, Revenue ($m), 2005-2010
Figure 21: Macular Degeneration Therapeutics Market, the UK, Forecast ($m), 2010-2018
Figure 22: Macular Degeneration Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 23: Macular Degeneration Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 24: Opportunity and Unmet Need in the Macular Degeneration Therapeutics Market
Figure 25: Strategic Competitor Assessment of the Major Marketed Products in AMD, 2011
Figure 26: Clinical Study Details - Lucentis
Figure 27: Clinical Study Details - Visudyne
Figure 28: Clinical Study Details - Macugen
Figure 29: Macular Degeneration Therapeutics - Pipeline by Phase of Development, 2011
Figure 30: Macular Degeneration Therapeutics - Technology Trends Analytics Framework, 2011
Figure 31: Macular Degeneration Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 32: Macular Degeneration Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 33: Clinical Study Details - VEGF Trap-Eye
Figure 34: Macular Degeneration Therapeutics - Clinical Trials by Country, 2011
Figure 35: Macular Degeneration Therapeutics - Clinical Trials by Phase, 2011
Figure 36: Macular Degeneration Therapeutics - Clinical Trials by Status, 2011
Figure 37: Macular Degeneration Therapeutics - Overall Sponsors, 2011
Figure 38: Macular Degeneration Therapeutics - Prominent Sponsors, 2011
Figure 39: Macular Degeneration Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 40: Key Events Competition in the Macular Degeneration Therapeutics Market, 2011
Figure 41: Implications for Future Market Competition in the Macular Degeneration Market, 2011
Figure 42: Macular Degeneration Therapeutics Market - Pipeline by Company, 2011

COMPANIES MENTIONED

Genentech /F. Hoffmann-La Roche
Bayer AG
Regeneron Pharmaceuticals, Inc.

Ask Your Question

Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: